New pharmaceutical treatments for non-Alzheimer dementias
Following on from information provided to NICE by the company in June 2004 the appraisal of New pharmaceutical treatments for non-Alzheimer dementias was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 380
Referral date 01 March 2003
Topic area
  • Central nervous system
  • Mental health and behavioural conditions
  • Therapeutic procedures

Provisional Schedule

Information meeting with consultees: 25 March 2004
Closing date for invited submissions / evidence submission: 03 June 2004
Final scope published: February 2004
1st appraisal committee meeting: 01 January 2100
2nd appraisal committee meeting: 25 January 2005

Project Team

Assessment Group / Evidence Review Group: Southampton Health Technology Assessment Centre (SHTAC), University of Southampton
Communications manager: Phil Ranson
Executive Lead: Andrew Dillon
Project manager: Alana Miller
Technical Lead: Alastair Fischer

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
28 December 2022 Discontinued. Following on from information provided to NICE by the company in June 2004 the appraisal of New pharmaceutical treatments for non-Alzheimer dementias was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
10 February 2004 Date of Information Meeting for Consultees added.
12 March 2004 Expected date of issue amended to May 2005.
11 June 2004 This appraisal has now been halted following confirmation received by the Institute from the manufacturers that they have withdrawn the application to extend the license of donepezil within the European Union to include the treatment of vascular dementia while further data is obtained. The Institute will continue to monitor the progress of marketing authorisation of interventions for non-Alzheimer dementia and will contact consultees and commentators at such time as may be appropriate to resume the appraisal.

For further information on our processes and methods, please see our CHTE processes and methods manual